FDA Targets Experimental Multiple Sclerosis Treatment

Law360, New York (May 10, 2012, 2:50 PM EDT) -- The U.S. Food and Drug Administration on Thursday warned doctors and people suffering from multiple sclerosis and chronic cerebrospinal venous insufficiency about an experimental treatment called "liberation therapy" or "the liberation procedure," saying it can result in injury or death.

CCSVI is characterized by a narrowing of veins in the neck and chest, and liberation therapy uses balloon angioplasty devices or stents to widen narrowed veins in the chest and neck, the agency said. However, the FDA said it has learned of death, stroke, detachment and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.